

BÖLÜM

5

PROSTAT BEZİ HASTALIKLARI

Berrak Barutcu ASFUROĞLU¹
Umut ASFUROĞLU²

Vaka 1: Benign Prostat Hiperplazisi (BPH) Nodülü

Vaka 2: Post-biyopsi Hemoraji

Vaka 3: Transizyonel zonda PI-RADS 5 lezyon

Vaka 4: Periferal zonda PI-RADS 4 lezyon

Vaka 5: Periferal zonda PI-RADS 5 lezyon

Vaka 6: Periferal zonda PI-RADS 2 lezyon

¹ Uzm. Dr. Gaziantep Abdulkadir Yüksel Devlet Hastanesi, berrakbarutcu.bb@gmail.com

² Uzm. Dr. Gaziantep Abdulkadir Yüksel Devlet Hastanesi, umutasfuroglu@gmail.com

KAYNAKLAR

1. Ling D, Lee J, Heiken JP, et al. Prostatic carcinoma and benign prostatic hyperplasia: inability of MR imaging to distinguish between the two diseases. *Radiology*. 1986;158(1):103-107.
2. Schiebler ML, Tomaszewski JE, Bezzi M, et al. Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. *Radiology*. 1989;172(1):131-137.
3. Guneyli S, Ward E, Thomas S, et al. Magnetic resonance imaging of benign prostatic hyperplasia. *D/R*. 2016;22(3):215.
4. Barrett T, Rajesh A, Rosenkrantz AB, et al. PI-RADS version 2.1: one small step for prostate MRI. *Clinical radiology*. 2019.
5. Oyen RH, Van de Voorde W, Van Poppel H, et al. Benign hyperplastic nodules that originate in the peripheral zone of the prostate gland. *Radiology*. 1993;189(3):707-711.
6. Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. *Radiology*. 2010;257(3):715-723.
7. Kitzing YX, Prando A, Varol C, et al. Benign conditions that mimic prostate carcinoma: MR imaging features with histopathologic correlation. *Radiographics*. 2016;36(1):162-175.
8. Parsons BA, Hashim H. Emerging treatment options for benign prostatic obstruction. *Current urology reports*. 2011;12(4):247-254.
9. Lusuardi L, Hruby S, Janetschek G. New emerging technologies in benign prostatic hyperplasia. *Current opinion in urology*. 2013;23(1):25-29.
10. White S, Hricak H, Forstner R, et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. *Radiology*. 1995;195(2):385-390.
11. Barrett T, Vargas HA, Akin O, et al. Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. *Radiology*. 2012;263(3):751-757.
12. Qayyum A, Coakley FV, Lu Y, et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. *American Journal of Roentgenology*. 2004;183(4):1079-1083.
13. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging-reporting and data system: 2015, version 2. *European urology*. 2016;69(1):16-40.
14. Kayhan A, Fan X, Oommen J, et al. Multi-parametric MR imaging of transition zone prostate cancer: Imaging features, detection and staging. *World journal of radiology*. 2010;2(5):180.
15. Chesnais A, Niaf E, Bratan F, et al. Differentiation of transitional zone prostate cancer from benign hyperplasia nodules: evaluation of discriminant criteria at multiparametric MRI. *Clinical radiology*. 2013;68(6):323-330.
16. Rouvière O, Raudrant A, Ecochard R, et al. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. *European radiology*. 2003;13(5):931-942.
17. Yacoub JH, Oto A, Miller FH. MR imaging of the prostate. *Radiologic Clinics*. 2014;52(4):811-837.
18. Furlan A, Borhani AA, Westphalen AC. Multiparametric MR imaging of the prostate: interpretation including prostate imaging reporting and data system version 2. *Urologic Clinics*. 2018;45(3):439-454.
19. Salerno J, Finelli A, Morash C, et al. Multiparametric magnetic resonance imaging for pre-treatment local staging of prostate cancer: A Cancer Care Ontario clinical practice guideline. *Canadian Urological Association Journal*. 2016;10(9-10):332.
20. Karaarslan E. Prostat Kanseri Evrelemesi. 2017.
21. Reddy MN, Verma S. Lesions of the seminal vesicles and their MRI characteristics. *Journal of clinical imaging science*. 2014;4.
22. Chan TW, Kressel HY. Prostate and seminal vesicles after irradiation: MR appearance. *Journal of Magnetic Resonance Imaging*. 1991;1(5):503-511.
23. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. *European urology*. 2017;71(4):618-629.
24. Krieger JN, Nyberg Jr L, Nickel JC. NIH consensus definition and classification of prostatitis. *Jama*. 1999;282(3):236-237.
25. Murphy AB, Macejko A, Taylor A, et al. Chronic prostatitis. *Drugs*. 2009;69(1):71-84.
26. Cruz M, Tsuda K, Narumi Y, et al. Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. *European radiology*. 2002;12(2):357-365.
27. Sah VK, Wang L, Min X, et al. Multiparametric MR imaging in diagnosis of chronic prostatitis and its differentiation from prostate cancer. *Radiology of Infectious Diseases*. 2015;1(2):70-77.
28. Aineseder M, Rodriguez SC, Ocantes J. Chronic Prostatitis: Have we had other findings supporting PI RADS II on the prostate peripheral zone? 2018: *European Congress of Radiology*. 2018.